MK-677 vs HGH: What You're Actually Getting for the Money

You've been reading about growth hormone for three months. You understand the basics — IGF-1, pulsatile release, the sleep-dependent GH spikes. Now you're staring at two options: pharmaceutical HGH at somewhere north of $500/month, or MK-677 at $60–$90 for a month's supply from a peptide supplier. The question isn't whether they're the same thing. They're not. The question is what the gap between them actually costs you in outcomes, safety, and legal standing.

What MK-677 Actually Does (and Doesn't Do)

MK-677 (ibutamoren) is a ghrelin receptor agonist — it mimics ghrelin at the GHSR receptor, triggering the pituitary to release endogenous GH. It's oral, it's not a peptide, and it's not a SARM despite being perpetually mislabeled as one. A 2008 Nass et al. study published in the Journal of Clinical Endocrinology & Metabolism found that 25 mg/day of MK-677 in older adults increased IGF-1 levels by approximately 60% over 12 months and improved lean body mass. That's a real signal, not a supplement-tier placebo.

The ceiling is the pituitary itself. MK-677 amplifies what your own axis can produce. If your baseline GH output is already suppressed — from age, from prior steroid use, from pituitary pathology — MK-677 is working with diminished material. You can stimulate a quieter orchestra more loudly, but you're still limited by who showed up to play.

What Pharmaceutical HGH Actually Gives You

Pharmaceutical HGH is recombinant human growth hormone — somatropin — delivered subcutaneously, bypassing the pituitary entirely. You set the dose and inject it directly. Typical clinical dosing for adult GH deficiency starts around 0.2–0.4 mg/day per Endocrine Society guidelines, titrated against IGF-1 response and tolerability. This is precise. A physician can target a specific IGF-1 range (usually 200–300 ng/mL for adults in optimization contexts) and adjust accordingly.

The cost structure is punishing. Brand-name somatropin — Norditropin or Genotropin — runs $800–$1,200/month at US retail in 2026. Compounded somatropin from 503A or 503B pharmacies has created a lower-cost parallel track, with prices closer to $200–$350/month for GH-deficient patients using telehealth platforms. Online hormone programs that include compounded HGH typically require documented GH deficiency via stimulation testing before prescribing — which adds both cost and lead time to the on-ramp.

The Real Difference in Outcomes

For body composition in a healthy adult with intact GH secretion, MK-677 at 25 mg/day will produce a measurable IGF-1 elevation and modest lean mass gains over a 3–6 month window. It won't match the dose-titratable precision of exogenous HGH, but it also doesn't require a prescription, injection, or cold-chain storage.

The gap becomes decisive in four specific scenarios: GH-deficient patients, post-surgical pituitary cases, adults with confirmed IGF-1 below 100 ng/mL, and anyone targeting visceral fat loss. For visceral fat specifically, tesamorelin — a GHRH analogue with FDA approval for HIV-associated lipodystrophy — has a tighter evidence base for that endpoint than MK-677 does. Mixing up these mechanisms matters when you're trying to justify the cost.

MK-677 also raises cortisol and prolactin in some users. The Nass study flagged transient increases in fasting insulin and glucose — a real consideration for anyone pre-diabetic or tracking metabolic markers. Exogenous HGH carries its own insulin resistance issues, but they're more predictable and titratable.

The Legal and Access Picture in 2026

MK-677 occupies an odd regulatory space. The FDA sent warning letters to supplement retailers selling it in 2023, and by 2026 it has been formally classified as a drug under the FD&C Act, meaning it can't be legally sold as a supplement or research chemical in the US. It's still widely available through overseas suppliers and gray-market channels, but anyone selling it domestically as a "research compound" is operating outside current enforcement tolerance.

Pharmaceutical HGH is a Schedule III substance. It requires a valid diagnosis — adult GH deficiency confirmed via formal stimulation testing, or a specific approved indication. Prescribing it for anti-aging or performance reasons exists but carries legal exposure for the prescriber. Hormone optimization clinics that include HGH in their protocols generally use compounded somatropin and require a diagnostic workup to cover themselves.

Secretagogues as a Middle Path

The choice isn't binary. Growth hormone secretagogues like ipamorelin — a GH-releasing peptide — offer a prescribable, injectable middle path. Ipamorelin stimulates GH release with minimal effect on cortisol or prolactin compared to older GHRPs such as GHRP-6, and it's available through licensed telehealth clinics. A standard ipamorelin protocol runs 200–300 mcg subcutaneously before bed, usually stacked with CJC-1295 without DAC. Costs through System Labs and comparable platforms run $150–$250/month depending on formulation.

This gives you pituitary stimulation with physician oversight, real supply chain accountability, and IGF-1 monitoring — none of which you get from gray-market MK-677.

The Bottom Line

MK-677's price advantage is real, but it comes bundled with regulatory ambiguity, variable supply quality, and a mechanism capped by your pituitary's current output. Pharmaceutical HGH is more precise and more powerful, but it requires legitimate diagnosis, costs $200–$350/month even through compounding pharmacies, and carries more metabolic risk at aggressive dosing. For most adults with intact GH axes looking to optimize body composition, secretagogue protocols through licensed clinics — ipamorelin/CJC-1295 at $150–$250/month with IGF-1 monitoring — offer a better risk-adjusted outcome than either gray-market MK-677 or brand-name somatropin. The paper trail matters more than it did three years ago.

---

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---